+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review



The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review



Climacteric 18(4): 470-482



Estrogen replacement therapy (ERT) is a well-established method of managing climacteric symptoms in women approaching the menopause, but it is associated with a significant risk of endometrial hyperplasia if unopposed by concomitant progestogen administration. The levonorgestrel-releasing intrauterine system (LNG-IUS) offers a highly effective method of minimizing this risk and has additional benefits beyond endometrial protection. The LNG-IUS provides excellent contraception, which may still be necessary in perimenopausal women, and is suitable for women with underlying conditions that may preclude their use of estrogen-containing contraceptive methods. It can effectively manage bleeding problems through the transition from perimenopause into menopause, with many women developing amenorrhea. The LNG-IUS is well tolerated with a favorable safety profile, which generally mirrors that of women of reproductive age using it for contraception only. Moreover, the LNG-IUS plus ERT combination does not appear to be associated with clinically relevant effects on plasma lipids or other markers of cardiovascular risk. Women using the LNG-IUS plus ERT also experience improvements in quality of life, and adherence and continuation rates are high. This review will summarize the clinical evidence for the use of the LNG-IUS plus ERT in peri- and postmenopausal women and present the key attributes of this combined therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059083627

Download citation: RISBibTeXText

PMID: 25553775

DOI: 10.3109/13697137.2014.991302


Related references

Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy. Maturitas 48(1): 65-70, 2004

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao 32(9): 1350-1354, 2013

Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 18(10): 1060-1066, 2012

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. American Journal of Obstetrics and Gynecology 172(1 PART 1): 114-119, 1995

Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecologic Oncology 95(3): 762-764, 2004

Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial. Lancet (North American Edition) 356(9243): 1711-1717, 18 November, 2000

Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstetricia Et Gynecologica Scandinavica. 77(7): 758-763,., 1998

The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen. European Journal of Gynaecological Oncology 35(5): 492-498, 2014

Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstetricia et Gynecologica Scandinavica 82(6): 580-582, 2003

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: Clinical and endometrial responses. Maturitas 26(2): 103-111, 1997

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception 80(1): 84-89, 2009

The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Australian & New Zealand Journal of Obstetrics & Gynaecology 49(3): 316-322, 2009